Repurposing DPP-4 Inhibitors for Colorectal Cancer: A Retrospective and Single Center Study.

Cancers (Basel) · 2021 · PMC8306906 · PMID 34298800

Europe PMC DOI

hedged sentences

0.0310

closest p · 0.6× alpha

0.0960

boldest claim

The sentences

close-to-significantp = 0.031actually significant

As shown in Figure 4 A, our results suggested a significant or close-to-significant increase in lymphocyte count ( p = 0.031) and PNI ( p = 0.017) and decrease in NLR ( p = 0.070) and PLR ( p = 0.079) in good prognosis patients, whereas the change in the poor prognosis group was insignificant, suggesting that the change in these immune cell parameters can early predict the efficacy of DPP4-inhibitor on the prognosis of post-operative patients.

also in 171 other papers

showed a trendp = 0.096so close (0.05 < p ≤ 0.1)

Our pilot data showed that CRC patients with DPP4-inhibitor treatment showed a trend of higher post-operative lymphocyte count ( p = 0.096, data not shown) when compared to the control group.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.